It has been demonstrated that normalization of tumor vasculature, by targeting pro-angiogenic tyrosine kinase receptor, Vascular endothelial growth factor-2 (VEGFR-2), reprogram the tumor microenvironment and enhance cancer immunotherapy [11]. The gene discussed is NTRK1; the disease is neoplasm.